FDA
-
-
-
-
-
-
-
Algernon Pharmaceuticals Completes Name Change to Algernon Health
-
-
-
-
-
-
-
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
-
-
-
-
-
-
-
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
-
-
-
-
-
-
-
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
-
-
-
-
-
-
-
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
-
-
-
-
-
-
-
Algernon Pharmaceuticals Announces Plans for 2021
-
-
-
-
-
-
-
Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19
-
325,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

